This is not a financial advise and shouldnt be taken as such

Trevena

Trevena, Inc. is a company developing innovative drugs for pain management. With opioid crisis in the world they are trying to find drugs with benefits of opioid but without its addiction

The U.S. Food and Drug Administration (FDA) is reviewing oliceridine injection for the management of moderate to severe acute pain.

The Company‘s New Drug Application (NDA) submission for oliceridine was accepted for review by the FDA on January 2, 2018. The Prescription Drug User Fee Act (PDUFA) target date for completion of review by FDA of November 2, 2018 remains unchanged.

They say the new drug will help hospital patients who require an IV opioid will have an alternative and safe option

Oliceridine Injection

Oliceridine injection is an yet to be approved analgesic for pain management without adverse effects

#Stock price
Currently TRVN trades at 3.47

Many expects, its lead product Oliceridine will get FDA approval, if that happens expect the stock to break out potentially to 15 and it could very well be an aquisition target north of 1 billion..

#Flip side
If it doesnt get FDA approval, this could turn very bad for the company and could erase months of gain

So its a risky play!!! decision should come soon